Podcasts about Drug development

"I'd already finished my cardiovascular unit. I'd finished my pulmonary unit. I had never heard about this in any of my classes." That was Dr. Joel Bervell's reaction to discovering that a device used every day in hospitals -- the pulse oximeter -- reads less accurately on darker skin tones. He posted a 30-second video about this consequential discrepancy that, to his utter surprise, gained over 500,000 views by the next morning. That video launched Dr. Bervell into orbit as a social media presence and created his identity as The Medical Mythbuster. In just a few years, he's built a following of two million people, earned a Peabody Award and was named to the inaugural Time 100 Creators list, all while finishing his residency.  On this episode of Raise the Line, host Lindsey Smith welcomes Dr. Bervell to explore the roots of this kind of bias and the real world impact of drawing attention to it. “The most impactful biases in medicine exist because no one stops to ask who was included in the original data and who was left out,” Dr. Bervell explains. Stay tuned to also learn about: His YouTube animated series The Doctor is In which helps kids understand how their bodies work, as well as providing medical role models; How to build trust with marginalized communities; His forthcoming book, The Default Body which examines who medicine was actually designed for. Mentioned in this episode:Dr. Bervell on InstagramTikTok ChannelFacebook"The Doctor Is In" Show If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Despite gains in recent years, Black, Hispanic, and Asian communities are still under-represented in the U.S. nursing workforce. We're going to explore that gap and how to close it on this episode of Raise the Line from Elsevier with Dr. Ernest Grant, Vice Dean for Diversity, Equity, Inclusion and Belonging at the Duke University School of Nursing. "You get a patient who is more compliant when they see someone who looks like them, who is from their culture and who can advocate on their behalf," he tells host Lindsey Smith.  Dr. Grant bases that and other insights on a rich professional background that includes 50 years in nursing, being a leading advocate for his profession and breaking down barriers himself as a male nurse of color and the first man elected president of the American Nurses Association.  In this thoughtful conversation, Dr. Grant reflects on what it took to earn credibility in leadership roles, how he's navigating the political climate on DEI initiatives, and the causes and solutions to the persistent shortage in nursing faculty, among other pressing issues. Tune in for a uniquely-informed look at what it will take to build a stronger, more representative nursing profession. Mentioned in this episode: Duke University School of Nursing American Nurses Association If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

What does it take to compete on the world's biggest stage and then pivot to one of the most demanding training paths in professional life? Today's guest, Samantha "Sammy" Kolowrat, has done both, and she has some fascinating insights into the commonalities of those two worlds on this episode of Raise the Line. “Something that really drew me to medicine is the team atmosphere that's there as you work towards a common goal, and there's this level of intensity that's very reminiscent of the experiences I had as a professional athlete.” Originally from Prague, Kolowrat represented Czechia at six IIHF Women's World Championships and the 2022 Beijing Olympics, and also captained the Division I women's hockey team at the University of Vermont while earning degrees in biology and pharmacology.  As she starts an anesthesiology residency at Vanderbilt University, she credits her athletic career with shaping how she handles pressure, feedback, and teamwork in medicine. "The more I improve, the more knowledge I acquire, the more skills I hone, the better care my patients get," she tells host Lindsey Smith, describing what drew her to a field that rewards the same relentless fine-tuning as elite sports. This engaging conversation also explores: How crippling performance anxiety as a Division I athlete ended up preparing Kolowrat for the operating room; Why she was drawn to anesthesiology's "well-oiled machine" atmosphere; The mentorship gap she's working to close for the next generation of athlete-physicians. Mentioned in this episode: Vanderbilt University Anesthesiology Residency Program If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Dr. Mitch Shulman can be heard every weekday morning at 7:50 on The Andrew Carter Morning Show.

Plus: Redwire taps SpaceX's Starfall ship for pharma mission. And Datadog warns of lower usage by major AI customer. Imani Moise hosts. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

An 11-year-old boy in rural Zambia once told Dr. Genesis Mwamba that he was about to attend school wearing shoes for the first time in his life. That moment, Dr. Mwamba says, crystallized why he started the Lead Me Back Foundation to provide school supplies and other support to marginalized communities in his native country.   As you'll learn in this inspiring installment in our NextGen Journeys series, Dr. Mwamba started the foundation in 2021while still a medical student because he had experienced the power of education as an “equalizer” in his own life, taking him from humble roots to a career in medicine. He and his colleagues have grown the bootstrapped organization to a point where it now provides hundreds of thousands of people across the country with educational access, climate education and community health clinics. “I've always been drawn to opportunities and initiatives that bring help to humankind,” he tells Raise the Line host Dr. Parsa Mohri. This episode also explores: What building "with" a community rather than "for" it looks like in practice; The storytelling strategy that attracted donors and partners; How his mother's untimely death inspired his commitment to preventive medicine.   Mentioned in this episode: Lead Me Back Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Susan Wood, CEO of VIDA, develops AI-driven imaging-based biomarkers that quantitatively measure biological processes and disease states using imaging modalities such as CT, MRI, PET, and ultrasound. Unlike traditional visual image analysis, VIDA's technology extracts approximately 25,000 measurements per imaging timepoint, enabling detection of therapeutic responses at the sub-millimeter level. This convergence of advanced scanner technology, high-quality imaging data, and AI-powered analysis represents a significant new frontier in precision medicine and drug development. Susan explains, "I'll start with what VIDA brings in. Our background has been the development and validation of AI-driven imaging-based biomarkers. I'll start by defining a biomarker, specifically an imaging-based biomarker. It's a quantitative measurement derived from an imaging modality. An imaging modality can be a CT scan, an MRI, a PET scan, or an ultrasound, and the measurement reflects a biological process, a disease state, or a response to therapy. VIDA's formation was focused on the production and validation of those imaging-based biomarkers and on incorporating them into provider-based clinical workflows as well as clinical trial or drug development workflows." "I would say that in general, traditionally radiology has relied on radiologic images, those imaging modalities have been read visually. And if you read an image visually, there's just a fraction of information that you can get from those images versus reading them with these AI-generated processes. So there's less than 1% of that image you'll be able to understand the extent and the complexity of the measurements that image can offer. We read, or we combine that visual reading with a highly quantitative process. So for each imaging time point, we'll measure 25,000 measurements per imaging time point. Obviously that's well beyond what a human eye could do just from an efficiency standpoint, but certainly from a precision standpoint, they wouldn't be able to measure that level of precision in the imaging by an eyeball alone." #VIDA #AI #DigitalBiomarkers #MedicalImaging #Radiology #ClinicalTrials #DrugDevelopment #PrecisionMedicine #HealthcareInnovation #RespiratoryCare vidalung.ai Download the transcript here

Susan Wood, CEO of VIDA, develops AI-driven imaging-based biomarkers that quantitatively measure biological processes and disease states using imaging modalities such as CT, MRI, PET, and ultrasound. Unlike traditional visual image analysis, VIDA's technology extracts approximately 25,000 measurements per imaging timepoint, enabling detection of therapeutic responses at the sub-millimeter level. This convergence of advanced scanner technology, high-quality imaging data, and AI-powered analysis represents a significant new frontier in precision medicine and drug development. Susan explains, "I'll start with what VIDA brings in. Our background has been the development and validation of AI-driven imaging-based biomarkers. I'll start by defining a biomarker, specifically an imaging-based biomarker. It's a quantitative measurement derived from an imaging modality. An imaging modality can be a CT scan, an MRI, a PET scan, or an ultrasound, and the measurement reflects a biological process, a disease state, or a response to therapy. VIDA's formation was focused on the production and validation of those imaging-based biomarkers and on incorporating them into provider-based clinical workflows as well as clinical trial or drug development workflows." "I would say that in general, traditionally radiology has relied on radiologic images, those imaging modalities have been read visually. And if you read an image visually, there's just a fraction of information that you can get from those images versus reading them with these AI-generated processes. So there's less than 1% of that image you'll be able to understand the extent and the complexity of the measurements that image can offer. We read, or we combine that visual reading with a highly quantitative process. So for each imaging time point, we'll measure 25,000 measurements per imaging time point. Obviously that's well beyond what a human eye could do just from an efficiency standpoint, but certainly from a precision standpoint, they wouldn't be able to measure that level of precision in the imaging by an eyeball alone." #VIDA #AI #DigitalBiomarkers #MedicalImaging #Radiology #ClinicalTrials #DrugDevelopment #PrecisionMedicine #HealthcareInnovation #RespiratoryCare vidalung.ai Listen to the podcast here

With increasing efforts to scale into international markets, what can we expect from China's drug development industry? Joining the podcast is Daphne Smyth, head of global regulatory programs at Veristat, who shares her experience at this year's BioChina and what to expect for drug development on a global scale. Smyth explains why North America and Europe have been attractive market destinations for the Chinese market now more than ever, the regulatory reforms, and the potential bumps on the road getting Chinese drugs to foreign markets. Plus, host Deborah Borfitz gives you the latest news on the quantified financial value of risk-based quality management, a shingles vaccine for lowering dementia risk, a Parkinson's disease drug for treating depression, an AI for treating neuroblastoma, a link between hormonal birth control and brain health in older age, and Bayer's first strategic alliance with an academic medical center focused on clinical trials collaboration. Financial value of RBQM Study in Therapeutic Innovation & Regulatory Science News release from CluePoints Shingles vaccine may lower dementia risk Study in Annals of Internal Medicine  News on the Brown University website  Parkinson's drug for treatment-resistant depression Study in Nature Medicine  News on the Lund University website AI for improving neuroblastoma outcomes Research article in APL Quantum  News on the University of Utah website Brain-protecting effect of hormone therapies Study in NeuroImage News on the University of Kansas website  Bayer's alliance with academic medical center News on the University of Colorado Anschutz website Guest Daphne Smyth, head of global regulatory programs for Veristat  Article in Clinical Research News about opportunities in China The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.  

Core Skills for Biotech Drug Development Hello, this is Hall T. Martin with the Startup Funding Espresso -- your daily shot of startup funding and investing. Investors looking to invest in a biotech drug startup should diligence the team for key skills. Here are the key skills needed for biotech drug development: Knowledge of how to drug a target. This means identifying a molecule, often a protein, that is associated with the disease to be treated and could be treated by a drug. Ability to elucidate the mechanism of action. This is the process by which a drug functions to produce a pharmacological effect. Demonstrate safety and efficacy. This shows the therapeutic works and is non-toxic. Ability to design clinical trials to show safety and efficacy. This requires the ability to pick the right therapeutic indication and the appropriate patient population. Finally, understand the regulatory requirements for approval. This means identifying the right FDA path and the steps required to reach approval. Consider these skills in a founder before investing in a biotech drug startup. Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding. Let's go startup something today. _______________________________________________________ For more episodes from Investor Connect, please visit the site at: http://investorconnect.org Check out our other podcasts here: https://investorconnect.org/ For Investors check out: https://tencapital.group/investor-landing/ For Startups check out: https://tencapital.group/company-landing/ For eGuides check out: https://tencapital.group/education/ For upcoming Events, check out https://tencapital.group/events/ For Feedback please contact info@tencapital.group Please follow, share, and leave a review. Music courtesy of Bensound.

"We have an untapped army of 200,000 PAs that really could step up and drive some change in the healthcare system if we weren't restricted,” says Dr. Jennifer Kolb, capturing her motivation for pushing to update practice regulations for physician associates that date back more than 50 years.  As Chief Medical Officer and Senior Vice President of Clinical Affairs at the American Academy of Physician Associates, Dr. Kolb has been in the middle of the fight at the state and federal level to grant PAs more independence from physicians, full billing rights, and the increased ability to practice across state lines, among other changes.  In this pertinent conversation with Raise the Line host Lindsey Smith, Dr. Kolb explains how these updates could help close huge gaps in access to healthcare, better manage the fight against chronic diseases and improve patient outcomes.   Dr. Kolb also addresses:  Why the name shift from "assistant" to "associate" took her years to fully appreciate; How a 10-year gap in life expectancy across Chicago zip codes shapes her view of health equity; Why PA's shouldn't wait for permission to start making change in their communities. Mentioned in this episode:American Academy of Physician Associates   If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

“Environmental Sustainability can be a substantial differentiator for CDMOs”Jürgen Wieland, Development Environmental Sustainability Lead at Novartis, is engaged to integrate sustainability into development processes, including reducing the emissions of clinical trials.  Jürgen brings over 20 years of finance and controlling experience to his sustainability role at Novartis, where he's responsible for embedding environmental considerations across R&D and clinical operations. Before joining Novartis in 2011, he served as CFO of an NGO bringing solar energy to rural East Africa.In a recent PharmaSource podcast, Jürgen shares how pharmaceutical companies and their Contract, Development and Manufacturing Organization (CDMO) partners can reduce scope 3 emissions while improving operational efficiency—proving that sustainability and profitability are not mutually exclusive.Read the full article here.

Most adults who smoke want to quit, and about half try to do so in any given year, yet fewer than one in ten succeed. That persistent gap between intention and outcome is one of the central challenges in public health, and it's exactly the kind of problem that calls for new thinking about how to communicate with people to support behavior change.  Dr. Amanda Graham has been a leading force in doing just that in her role as chief health officer at Truth Initiative, the nation's largest non-profit public health organization dedicated to preventing addiction among young people and helping people of all ages to quit tobacco. On this episode of Raise the Line from Elsevier, Dr. Graham, who holds a PhD in clinical health psychology and has done 25 years of NIH-funded research focused on technology-based cessation interventions, helps us understand the interplay between behavioral science and digital communications in the field. "A well-timed message can really be powerful in interrupting what for many people is kind of an automatic behavior, especially via text, which data tell us is an extraordinarily powerful modality,” she explains to host Lindsey Smith.  Tune-in to understand where the field is heading, and to learn about: Why "push" technology may work better than apps and websites when it comes to breaking automatic behaviors; How the rise of e-cigarettes, nicotine pouches, and heated tobacco has scrambled decades of public health messaging; How highschool smoking rates plunged from over 30% to less than 2%. Mentioned in this episode: Truth Initiative Program with Mayo Clinic If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.

"I always remember feeling like I was part of the clean plate club," says Dr. Christle Guevarra, recalling a childhood spent quietly convinced that her weight was a matter of willpower. That belief followed her through a competitive powerlifting career and medical practice until she finally tried a GLP-1 medication herself and, as she describes it, the constant mental noise around food quieted down. Now a board-certified family and sports medicine physician, traveling team doctor for U.S. Figure Skating, and author of The Beginner's Guide to GLP-1s, Dr. Guevarra brings a rare combination of clinical authority and lived experience to the conversation around obesity medicine.  In this episode of Raise the Line from Elsevier, host Lindsey Smith talks with her about what's actually changed in how physicians understand the issue and what it means for patients. "The biggest thing is reframing how we approach weight loss. It's not just a willpower problem, it is a neurobiological problem." Tune in to learn about: Why she said no to a GLP-1 prescription for two years and what finally changed her mind; The real story behind concerns about muscle loss on these medications; What happens when the “food noise" goes silent and a new set of challenges takes its place.   Mentioned in this episode:  Dr. Christle's website If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

We love to hear from our listeners. Send us a message.Episode 133 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Aprea Therapeutics' CEO, Dr. Oren Gilad. They cover the evolution of precision oncology, the science of synthetic lethality, and how Aprea is developing next-generation therapies that target cancer's unique genetic vulnerabilities while improving safety and efficacy. Dr. Gilad also shares insights into biomarker-driven drug development, where precision medicine is headed as researchers pursue more effective treatments for patients with difficult-to-treat solid tumors, and more.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Millions of Americans were saddened and outraged by the Sandy Hook Elementary shooting in 2012 that took the lives of twenty children and six adults, and were left feeling helpless about the epidemic of gun violence in the U.S. that, sadly, continues to this day. But for our guest today, Shannon Watts, her feelings of devastation about the shooting turned to rage and fueled her unlikely rise to leading Moms Demand Action, which she grew into one of the largest grassroots organizations in the country, mobilizing millions of volunteers to push for stronger gun safety laws. “I wanted to stand shoulder to shoulder with a badass army of women because that's who gets things done in this country,” she says.    In this inspiring conversation with Raise the Line host Michael Carrese, Watts pulls back the curtain on how the group achieved its successes and the philosophy of "losing forward" that kept volunteers showing up year after year. In her recent book Fired Up, Watts describes how she is bringing insights from that experience to a new mission: helping women identify their values, abilities, and desires and acting on them without waiting until everything is perfect. Tune-in to learn about:  The "false fires" women mistake for passion; Why losing estrogen and testosterone in midlife might actually make women braver, not less so; The one exercise she does with every woman she coaches.  Mentioned in this episode: Fired Up book Moms Demand Action If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences.In this episode, Dr Camidge sat down with Funda Meric-Bernstam, MD, the department chair and Endowed Nellie B. Connally Chair in Breast Cancer, in the Department of Investigational Cancer Therapeutics, medical director of the Khalifa Institute for Personalized Cancer Therapy, and a professor of breast surgical oncology at The University of Texas MD Anderson Cancer Center in Houston; as well as a regular member of Cancer Biology at the University of Texas Houston Graduate School of Biomedical Sciences.Drs Camidge and Meric-Bernstam discussed Dr Meric-Bernstam's evolution from a science-focused student into a leader in precision oncology and early-phase drug development. Dr Meric-Bernstam was raised in a hybrid fashion between the US and Turkey, attending a science-focused boarding school before beginning medical school in Turkey and ultimately restarting her medical education at the Yale School of Medicine in New Haven, Connecticut. Drawn to both the immediacy of surgery and the questions of basic science, she pursued a surgical residency with built-in research time, spending 2 years at the National Institute of Health studying translational regulation, an experience she credited with making her fearless in tackling the unfamiliar.In this discussion, Dr Meric-Bernstam offered a candid look at building a career without a clear roadmap. She emphasized that clinician-investigators must work hard, arguing that a meaningful clinical presence sharpens translational research by revealing patients' true unmet needs. Her work spanning cell signaling, mTOR biology, window-of-opportunity trials, and genomic testing led her to direct MD Anderson's personalized cancer therapy efforts and grow its phase 1 program.Beyond administration, Meric-Bernstam reflected on lessons from the lab, including a year of lost data that taught her to scrutinize primary results at every step, and her conviction in patient-derived models and co-clinical trials. Ultimately, Dr Meric-Bernstam described a transformational moment in oncology, where AI, comprehensive profiling, and newly druggable targets will reshape combination therapy. She concluded by reaffirming her mission to improve cancer outcomes, calling it the best job in the world.

In the United States, nearly 70% of people say they want to die at home, yet the majority still die in medical settings, often after receiving care that may not match their goals and values. Closing that gap between preference and reality is at the heart of the work being done by End Well, a nonprofit dedicated to transforming how we think about, plan for, and experience the end of life. "The gap isn't about people wanting the wrong things. It's that our culture and our incentives aren't aligned with helping those wishes actually happen at the end of life,” says Dr. Shoshana Ungerleider, End Well's founder and president.  As Dr. Ungerleider explains to Raise the Line host Michael Carrese, End Well sponsors an annual symposium and year-round activities to bring together clinicians, patients, caregivers, and innovators to improve that alignment. Key steps include earlier integration of palliative care, allowing providers time for listening and goal setting with patients, and normalizing conversations about what matters most to people. This compelling conversation on reframing end of life care also covers how to bring wonder, joy, and hope into end-of-life conversations, and End Well's work to change how death is portrayed in the media. Mentioned in this episode:End Well If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode, we cut through the hype surrounding one of the fastest-growing trends in health and fitness: peptides. Joining us is Dr. Leigh Baxt, a translational scientist with experience advancing more than 30 therapeutic programs across oncology, metabolic disease, infectious disease, and regenerative medicine. Drawing on her background at Brown University, Stanford University School of Medicine, and Harvard Medical School, Dr. Baxt explains how drugs move from promising laboratory discoveries to proven human therapies, and why that process matters. We explore why peptides have become so popular, how social media has outpaced the science, and what people often misunderstand about anecdotal success stories, animal research, and theoretical mechanisms. We also discuss why many compounds that appear promising early in development never become approved treatments, the biological risks of manipulating growth and repair pathways, and where commonly discussed peptides like BPC-157, TB-500, MOTS-C, and KPV currently stand from an evidence perspective. Finally, we tackle some of the biggest misconceptions surrounding Big Pharma, patentability, regulation, and what consumers should expect as peptide oversight continues to evolve. Whether you're considering peptides yourself or simply want to separate scientific evidence from internet marketing, this episode provides the framework needed to evaluate the claims you're seeing online. Coach VinnyEmail: vinny@balancedbodies.ioInstagram: vinnyrusso_balancedbodiesFacebook: Vinny Russo Dr. ErynEmail: dr.eryn@balancedbodies.ioInstagram: dr.eryn_balancedbodiesFacebook: Eryn Stansfield Dr. Leigh BaxtEmail: baxt.leigh@gmail.com Instagram: sciencemomscicommLeigh collaborates heavily with unbiased science: https://www.unbiasedscience.com/ LEGION 20% OFF CODEGo to https://legionathletics.com/ and use the code RUSSO for 20% off your order!

While Elsevier's most recent Clinician of the Future Report shows increasing adoption of artificial intelligence tools among physicians and nurses, and optimism that they will improve quality of care in the future, a majority raised concerns about trust and reliability. To increase the level of trust, 60% said transparent citations of evidence-based and peer-reviewed research will be key. How to provide that transparency is our focus today as Raise the Line host Lindsey Smith welcomes Elsevier colleagues Rhett Alden and Raman Kaur to guide us through the complexities involved, including the concept of traceability and what role it plays in how AI tools such as Elsevier's ClinicalKey AI are built and deployed.  “Traceability changes the confidence that a clinician has in an AI tool so that they aren't trusting the AI, they're trusting the underlying evidence they're consuming from the AI-assisted platform,” says Raman, who brings years of experience as a primary care practitioner to her work.  It's also important, Rhett adds, to provide additional information, pulled from both the clinician's query and the patient's medical record, to inform clinical thinking. “ClinicalKey AI can be more than a response engine by establishing a larger context to provide a more precise answer for that individual patient.” In this thought-provoking discussion, these experts also provide insights on: Mitigating bias in AI results; Using AI responsibly with sustainability in mind; What type of clinician will benefit most from AI Mentioned in this episode: ClinicalKey AI Clinician of the Future Report If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Welcome to IDEA Collider with your host, Rick Ritacco.  In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of experience translating complex scientific concepts into relevant narratives. Sue discusses the unique challenges biotechs face with early positioning, explaining why teams often struggle with the paradox of having immediate scientific certainty about a molecule but immense clinical uncertainty about its future.  We explore how to simplify scientific messaging without "dumbing it down," and Sue shares three proven strategies: reappropriating non-pharma nomenclature, evolving familiar drug classes, and focusing on tangible clinical outcomes. Sue also highlights the importance of cross-functional alignment, noting that a team's conviction to execute a narrative often matters more than having absolute precision.  Tune in to hear her hilarious origin story involving the Boston Globe and oat bran donuts, and learn actionable advice on what biotechs should immediately remove from their websites. Don't forget to Like, Share, Subscribe, Rate, and Review!    Keep up with Sue Wood; LinkedIn: https://www.linkedin.com/in/susan-wood-266631244/    Follow IDEA Pharma On; Website: https://www.ideapharma.com/    Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of ACRO's GCP, Tinaya Gray (Executive Director, Site Engagement & PACE at ICON plc), Jan Hewett (SVP, FDA Regulatory Advisor at Advarra), and Jackie Kent (Independent Advisor) unpack the work of ACRO's dive team on representative, generalizable clinical trial data at the 2025 Innovation Network Gathering. Together, they explore why clinical trial populations still fail to reflect real-world patients, and what's been holding the industry back from meaningful progress.The conversation goes beyond identifying the problem. The group shares how a diverse set of stakeholders were able to align around practical, implementable solutions. They also discuss how industry can pilot new approaches, engage broader stakeholders, and turn promising ideas into standard practice. This episode offers a candid and solutions-oriented look at how to generate clinical data that truly supports better decision-making for all patients.

In this episode, Boyds' experts explore the emerging field of live biotherapeutic products (LBPs), explaining what they are, how they differ from everyday probiotics, and their roots in microbiome-based therapies, including fecal microbiota transplantation (FMT). Katherine and Celine discuss the evolving regulatory landscape, comparing the FDA's guidance and recent approvals with the more cautious approach taken by the EMA and national authorities across Europe. They also examine the scientific, manufacturing, and clinical development challenges facing LBP developers, including product consistency, mechanism of action, safety considerations, and clinical trial design.

It's been one year since the U.S. Centers for Disease Control and Prevention, in an unprecedented move, dismissed all the members of its Advisory Committee on Immunization Practices (ACIP), kicking off what would turn out to be a very concerning and busy year for infectious disease specialists.  We're going to recap this turbulent period – which includes a resurgence of measles, an unusually rough flu season, the emergence of a new COVID strain and outbreaks of hantavirus and Ebola – with Dr. William Schaffner, one of the country's most frequently quoted medical experts on infectious disease, vaccination, and public health. As a member of ACIP for decades, Dr. Schaffner brings unique insight into the dismantling of the committee and the distrust of vaccines that lies at the root of the changes. As he explains to Raise the Line host Lindsey Smith, while many vaccine critics are beyond reach, there are those he describes as vaccine hesitant that may be persuadable if the right approach is taken. “Beyond providing facts, we have to listen to them and respond to their concerns and make them feel comfortable. Information is fundamental, but behavior change only comes with a change in attitude.” Tune in for a wealth of wisdom and context that includes observations on: What's complicating containment of the Ebola outbreak; Challenges in public health communication in the current social media environment; What grade health authorities should get on their response to the hantavirus outbreak. Mentioned in this episode:Vanderbilt University School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

David Stamler, M.D., Chief Executive Officer AlterityTherapeuticsAlterity Therapeutics (NASDAQ: ATHE & ASX: ATH)www.alteritytx.com  David Stamler, M.D., Chief Executive OfficerDavid Stamler, M.D. is Chief Executive Officer and a Managing Director, and previously served as Alterity's Chief Medical Officer and Senior Vice President, Clinical Development. Dr Stamler has extensive drug development expertise spanning early-stage research through late-stage clinical trials, with three FDA drug approvals in neurology.Prior to joining Alterity, Dr. Stamler served as the Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries after Teva acquired Auspex Pharmaceuticals where he was Chief Medical Officer.Prior to Auspex, he served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., and Head of Drug Development at Prestwick Pharmaceuticals, Inc. Before Prestwick, Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc., and as Vice President, Clinical Research Center at Fujisawa Research Institute of America. Dr. Stamler began his career at Abbott Laboratories where he served in various positions including Director of Clinical Research, Pharmaceutical Products for the International Division.Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.

Geoff Rhyne, Co-Founder and CEO of IDefine, discusses the mission to advance research into Kleefstra syndrome, a rare genetic disorder, and to find a treatment where there is currently none. This organization of parents of children with KS is advocating for broader genetic sequencing to identify KS patients and differentiate the condition from other possible diagnoses, such as autism. Their research strategy is to first build the necessary infrastructure, including real-world data, model systems, and clinical guidelines, to de-risk the process for researchers and directly fund drug development. Geoff explains, "We're dedicated to advancing research, building community, and driving progress for Kleefstra syndrome. And the inspiration behind it is that a bunch of parents had impacted children. And, namely, for me, my daughter Ella received her diagnosis on February 26th, 2019. You asked a rare disease parent. Their diagnosis day and odds are they'll be able to rattle off pretty quickly because it is life-altering and changing. And once we looked around the landscape of Kleefstra syndrome and what was being done, we identified a need. And so a group of other parents and I came together and founded the organization in 2020."   "KS is one of these rare genetic disorders, and it affects brain development and basically every aspect of a child's life. And it could encompass developmental delays, feature delays, seizures, kidney issues, and cascading other conditions. So what happens with KS is that when you get the diagnosis, folks have often gone on a diagnostic odyssey. It's very rare that folks are being identified early on. And so we're part of that cohort that believes there are many more patients out there with KS, but the diagnostic odyssey is a real challenge. And so we typically will see kids receiving their diagnosis from three years to we've had someone diagnosed at 40 before, which is just a crazy experience as you can imagine." #IDefine #KleefstraSyndrome #EHMT1 #RareDisease #RareDiseaseResearch #NeurodevelopmentalDisorders #GeneticDisorders #PatientAdvocacy #CaregiverSupport #FamilyLedResearch #RareDiseaseCommunity #PrecisionMedicine #Genomics #MedicalResearch #ClinicalResearch #TranslationalResearch #DiagnosticJourney #PatientSupport #ResearchFunding #InclusiveCare #PatientVoices #RareDiseaseAwareness IDefine.org Listen to the podcast here  

Geoff Rhyne, Co-Founder and CEO of IDefine, discusses the mission to advance research into Kleefstra syndrome, a rare genetic disorder, and to find a treatment where there is currently none. This organization of parents of children with KS is advocating for broader genetic sequencing to identify KS patients and differentiate the condition from other possible diagnoses, such as autism. Their research strategy is to first build the necessary infrastructure, including real-world data, model systems, and clinical guidelines, to de-risk the process for researchers and directly fund drug development. Geoff explains, "We're dedicated to advancing research, building community, and driving progress for Kleefstra syndrome. And the inspiration behind it is that a bunch of parents had impacted children. And, namely, for me, my daughter Ella received her diagnosis on February 26th, 2019. You asked a rare disease parent. Their diagnosis day and odds are they'll be able to rattle off pretty quickly because it is life-altering and changing. And once we looked around the landscape of Kleefstra syndrome and what was being done, we identified a need. And so a group of other parents and I came together and founded the organization in 2020."   "KS is one of these rare genetic disorders, and it affects brain development and basically every aspect of a child's life. And it could encompass developmental delays, feature delays, seizures, kidney issues, and cascading other conditions. So what happens with KS is that when you get the diagnosis, folks have often gone on a diagnostic odyssey. It's very rare that folks are being identified early on. And so we're part of that cohort that believes there are many more patients out there with KS, but the diagnostic odyssey is a real challenge. And so we typically will see kids receiving their diagnosis from three years to we've had someone diagnosed at 40 before, which is just a crazy experience as you can imagine." #IDefine #KleefstraSyndrome #EHMT1 #RareDisease #RareDiseaseResearch #NeurodevelopmentalDisorders #GeneticDisorders #PatientAdvocacy #CaregiverSupport #FamilyLedResearch #RareDiseaseCommunity #PrecisionMedicine #Genomics #MedicalResearch #ClinicalResearch #TranslationalResearch #DiagnosticJourney #PatientSupport #ResearchFunding #InclusiveCare #PatientVoices #RareDiseaseAwareness IDefine.org Download the transcript here

Artificial intelligence is reshaping clinical research, but its impact extends far beyond automation. In this episode of ACRO's Good Clinical Podcast, host Sophia McLeod is joined by Paulo Limgenco (VP, Business Operations at YPrime) and Michael Tucker (VP, Patient Experience - Commercial at Medidata) to explore how AI and digital technologies are helping the industry build more sustainable, efficient, and patient-centered clinical trials.From protocol optimization and site selection to localization and decentralized trial models, the conversation examines how AI can reduce operational burdens, minimize waste, and expand access to research opportunities for underrepresented populations. The discussion also highlights the importance of responsible AI adoption, including strong governance frameworks, data stewardship, and human oversight.Tune in for an insightful conversation on how the industry is balancing innovation and responsibility while working toward a future where clinical trials are more efficient, inclusive, and sustainable for patients, sites, sponsors, and communities worldwide.

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the intricacies of pharmaceutical portfolio strategy.  This episode has accompanying slides that can be found on YouTube https://youtu.be/DKdy_MShWBA They tackle the growing view that the pharmaceutical industry doesn't just have a science problem; it has an execution problem. Alex breaks down how human biases, such as confirmation bias and champion bias, can derail clinical development and lead to poor portfolio choices. They emphasize that stopping a failing project early is just as critical to an organization's overall success as advancing a good one.  The episode explores successful decision-making frameworks from top-performing companies, analyzing how AstraZeneca's 5Rs framework reversed late-stage failures and examining structured matrices such as Roche's RAVE, Amgen's RAVE, and Pfizer's DICE. Alex also highlights Eli Lilly's highly successful Chorus unit and their use of AI to drive objective resource allocation. Tune in to hear why relying solely on standard Probability of Technical Success (PTS) models or Risk-Adjusted NPV is flawed, how operational issues drive numerous Phase 3 failures, and the incremental but powerful role machine learning will play in the next generation of drug development.

"Do nothing for us without us." According to today's guest Robyn Bussey, that operating principle is the basis for effective community health work. "You don't go into a community and dictate. You go and listen and trust and be a partner," she adds. As you'll learn in this enlightening conversation, Bussey is following that approach in her current work as Just Health Director at the Partnership for Southern Equity, an Atlanta-based nonprofit advancing racial equity and shared prosperity across the South.  On this episode of Raise the Line from Elsevier, Bussey provides illuminating  examples of community-rooted work in South Fulton County and rural Georgia, and explains why community health workers may be the most underutilized asset in addressing health disparities. This wide-ranging interview with host Michael Carrese also explores: Bussey's candid perspective on what happened to the surge of interest in health equity that occurred during COVID; Why life expectancy gains in many Southern states have lagged behind the rest of the country; Her advice to students and early-career clinicians about where they're needed most.   Mentioned in this episode:  Partnership for Southern Equity If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this sponsored episode of The Top Line, experts from Myriad Genetics join host Stephanie Butler to examine how tumor-informed molecular residual disease, or MRD, testing is beginning to redefine what early insight can mean in oncology drug development. As biomarker-driven therapies become more precise, the ability to understand response earlier and more clearly is increasingly being viewed as foundational to smarter development strategy. The discussion looks at how ultrasensitive, tumor-informed MRD assays can help track response over time, potentially surface deeper signals earlier and inform decisions that shape trial design, patient selection and regulatory direction. It also considers why these capabilities may become more important as oncology programs face growing pressure to balance speed, flexibility and evidence generation. Listeners will hear why early diagnostic strategy is increasingly seen as a competitive differentiator, how MRD can help teams make better decisions sooner and why its role in oncology development is expected to continue to evolve and expand.See omnystudio.com/listener for privacy information.

How can artificial intelligence help get the right drugs to the right patients faster, but without losing sight of the human side of healthcare?In this episode, host Elaine Hamm, PhD, sits down with Rafael Rosengarten, PhD, CEO and Co-Founder of Genialis, for a thoughtful conversation about the evolution of AI in biotech and its growing role in precision oncology. Drawing on more than a decade of experience at the intersection of machine learning and life sciences, Rafael shares how Genialis is building AI-powered foundation models of cancer biology to help pharmaceutical companies improve clinical trial success and accelerate drug development. The discussion also explores the promises and challenges of AI, from data quality and bias to the broader societal implications of increasingly intelligent technologies. In this episode, you'll discover:How AI foundation models are being used to reduce clinical trial failure in oncology.How new approaches to AI can unlock valuable insights from limited clinical datasets.The opportunities and risks of AI in healthcare, education, and society – and why human judgment remains essential.Tune in to hear what it takes to build trustworthy AI healthcare technologies and why the future of biotech still depends on human creativity and critical thinking.Links:Connect with Rafael Rosengarten, PhD, and learn about Genialis and The Alliance for Artificial Intelligence in Healthcare.Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine.Register for the Fat Tuesday Reception at BIO 2026 and check out Elaine's panel on Tuesday 6/23.Connect with Ian McLachlan, BIO from the BAYOU producer.Learn more about BIO from the BAYOU - the podcast.Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

External control arms are becoming increasingly important in drug development, but creating valid comparisons requires more than matching patient populations. In this episode, I speak with Ben Ackerman, Director of Real-World Biostatistics at GSK, about one of the most overlooked challenges in external control arm studies: endpoint bias. We discuss why differences in how outcomes are measured can influence study results, what researchers should consider when designing studies, and how the field is evolving to address these challenges. If you work with real-world evidence, causal inference, or innovative clinical trial designs, this episode offers valuable insights into improving the credibility and transparency of external control arm analyses.

What does it take to run successful clinical trials across borders? Tune in as Chris Boone (Group VP, Research, Health & Life Sciences at Oracle) and Alicia Baker McDowell (VP & Head of Global Regulatory Strategy at Fortrea) explore the shift from transactional outsourcing to truly co-created partnerships.They discuss how sponsors, CROs, and tech partners are redefining collaboration, tackling data fragmentation, and striking the right balance between global consistency and local execution to deliver more effective clinical trials worldwide.

#thismorning | #Molecule to #Medicine: How Daraxonrasib is #Rewriting Pancreatic #Cancer #Drug #Development | Andrew R. Snyder, PhD., Monash University | #Tunein: broadcastretirementnetwork.com #Aging, #Finance, #Lifestyle, #Privacy, #Retirement, #wellness

Welcome back to the communal Schauer, make sure to don your tin foil hat because this week we're wading into the murky waters of interventionism and bungled progress. A word of warning to those of childbearing age: I swear a lot in this and it has been scientifically proven that profanity makes your ovaries grieve.  Tear. Pour. Live More. Go to https://LiquidIV.com and get 20% off your first purchase with code SCHAUER at checkout Download Hily Dating App from the App Store or Google Play, or visit https://hily.go.link/jRMKW And yes, I do apologize for the late upload, I'm trying to get the hang of recording at home. I appreciate everyone's patience, you all are incredible and should be celebrated. I hope you all enjoy this week's episode! The Allen Institute's Collab w/ KEXP  https://alleninstitute.org/kexp  I helped with this! General Resources: Alzheimer's Disease https://emedicine.medscape.com/article/1134817-overview#a2  Anatomy, Abdomen and Pelvis: Celiac Ganglia https://www.ncbi.nlm.nih.gov/books/NBK538129/#article-19097.s6 Federal Food, Drug, and Cosmetic Act of 1938 https://www.ncbi.nlm.nih.gov/books/NBK585046/ Toxic Effects of Mercury on the Cardiovascular and Central Nervous System https://pmc.ncbi.nlm.nih.gov/articles/PMC3395437/  Tampons as a source of exposure to metal(loid)s https://www.sciencedirect.com/science/article/pii/S0160412024004355  Patents on Psychedelics: The Next Legal Battlefront of Drug Development  https://harvardlawreview.org/forum/no-volume/patents-on-psychedelics-the-next-legal-battlefront-of-drug-development/ Caffeine-Induced Psychosis: A Case Report and Review of Literature https://pmc.ncbi.nlm.nih.gov/articles/PMC11376648/  The effect of caffeine and stress on auditory hallucinations in a non-clinical sample https://www.sciencedirect.com/science/article/abs/pii/S019188691000591X  Scientists Stop Pancreatic Cancer Before It Starts in Landmark Preclinical Study https://scitechdaily.com/scientists-stop-pancreatic-cancer-before-it-starts-in-landmark-preclinical-study/  The Brain Waste System Disrupted by Alzheimer's Mapped https://neurosciencenews.com/glymphatic-brain-waste-clearance-30785/  The Resurgence of Hallucinogen Drugs in Clinical Research https://www.sciencedirect.com/science/article/pii/S0034837625001457  Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study https://pubmed.ncbi.nlm.nih.gov/4575166/  This study is from 1973 - if you would do me the favor of scrolling down to the “similar articles” section I'd like you to note the dates of publication for related research. If you're seeing what I'm seeing, psychedelics could've really helped a lot of people. Books Clean: The New Science of Skin and the Beauty of Doing Less - James Hamblin Natural Capitalism: Creating the Next Industrial Revolution - Paul Hawken Undermining Science: Suppression and Distortion in the Bush Administration - Seth Shulman Sweet and Deadly: How Coca-Cola Spreads Disinformation and Makes Us Sick - Murray Carpenter How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence - Michael Pollan Unwell Women: Misdiagnosis and Myth in a Man-Made World - Elinor Cleghorn A History of Transgender Medicine in the United States: From Margins to Mainstream - Carolyn Wolf-Gould, Dallas Denny, Jamison Green, Kyan Lynch, Editors Food & Lobbying Resources: Nutrition Websites & Databases https://libguides.regiscollege.edu/nutrition/intro EWG's Food Scores https://www.ewg.org/foodscores/ Open Secrets https://www.opensecrets.org/  Learn more about your ad choices. Visit podcastchoices.com/adchoices

As concerns escalate about the deadly Ebola virus outbreak in Africa, we bring you the unique insights of Dr. Peter Piot, a renowned microbiologist who co-discovered the virus 50 years ago during the first recorded outbreak of the disease. His on-the-ground account of that crisis was provided to us in April before the current outbreak was declared, but it contains valuable historical perspective and shares lessons learned that he carried forward in his consequential career.  “What I saw from the beginning is the most important thing is to listen to people and that you need to act fast to save lives, before you have the evidence you would like to have.”    He followed his contributions on Ebola by diving into the fight against HIV/AIDS, eventually reshaping global response in leadership roles at the World Health Organization and United Nations. As he shares with host Lindsey Smith, the learnings in that case were more pragmatic than scientific. “We had to redefine HIV/AIDS not as a medical problem but as an economic and security problem in order to get it on the political agenda.”  Tune in for a fascinating episode that takes you from the gritty frontlines of public health crises to the battles for funding and attention in the halls of power as Dr. Piot shares what it actually takes to move the world to respond effectively to health threats. Mentioned in this episode: London School of Hygiene & Tropical Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

What happens when a founder nearly loses everything?In this episode of The Authority Company Podcast, Joe Pardavila sits down with neuroscientist, entrepreneur, and Clinilabs founder Dr. Gary Zammit to discuss the emotional reality of entrepreneurship, surviving the Great Recession, building elite teams, and the future of AI in medicine.Gary shares brutally honest stories about nearly losing his company, struggling to make payroll, and even telling his wife she should divorce him to protect their family financially. He also explains why the future of life sciences depends on more than innovation alone.This conversation explores resilience, leadership, culture, clinical trials, pharmaceutical misconceptions, and the people behind breakthrough medicine.Topics Covered:• The emotional cost of entrepreneurship• Surviving financial collapse during the recession• Why pharmaceutical companies get misunderstood• The difference between A players and superstars• How elite teams are built• Why company culture matters during chaos• The future of AI in healthcare and drug development• Clinical trials explained simply• Leadership lessons from failure• Persistence and resilience in business Chapters00:00 Intro00:01 Why Pharma Gets Such Bad Press02:47 Revealing the Hidden Struggles Behind the Business05:03 Nearly Losing the Company During the Recession07:12 The Moment He Asked His Wife for a Divorce09:08 Managing Morale During Financial Collapse11:21 Explaining Neuropsychiatric Drug Development12:39 Why CNS Research Became So Risky15:23 How the Company Turned Around17:07 Building and Retaining A Players19:25 Can You Create an A Player?21:00 A Players vs Superstars22:19 Building World-Class Processes23:14 How Technology Changed Clinical Trials25:27 AI and the Future of Medicine28:29 The Current State of Clinical Research30:00 Persistence Through Adversity31:02 Outro

Many of the forces driving species to extinction—habitat destruction, pollution, climate change—also fuel the spread of disease. Plants and animals around the globe are facing their own little pandemics, from cancer to fungal diseases. But what if we could treat them with cutting-edge medicines? Is there something drug developers could do to help? Chemist Tim Cernak thinks so. He has been developing drugs for people for 20 years, but his patient roster has started to include sea turtles, frogs, and giant reptiles. He talks with Flora about why he's making drugs for wildlife and why more chemists should join in. Guest: Dr. Tim Cernak is an associate professor of medicinal chemistry at the University of Michigan. Other episodes you may enjoy: Raising A New Generation Of Bat Conservationists In West Africa How Conservation Efforts Brought Rare Birds Back From The Brink Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This episode features three leading statistical methodology experts discussing the role, impact, and future of methodology groups in the pharmaceutical industry. They explore organizational structures, skill sets, AI integration, and strategies to accelerate adoption of innovative methods.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jeff Jonas, M.D., CEO of Tortugas Neuroscience, talks about the company's April 2026 launch and how in-licensed development assets were chosen. Jeff explains his strategy of chasing fast proof of safety and efficacy in humans, not animals, and talks about what product differentiation looks like in brain disorders, from adjusting indication targets to conducting head-to-head trials. He also reflects on the opportunity with psychedelics, RFK Jr.'s quest to curb SSRI prescriptions, the payer landscape in CNS disorders, and more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts discuss efficacy, safety, biomarkers, and future directions in bladder cancer treatment.

What does it take to move a scientific idea from the bench to patients, especially in some of biotech's most challenging therapeutic areas? In this episode, Elaine Hamm, PhD, sits down with Gareth Willis, PhD, COO of Otologic Pharmaceutics and CEO of Exosla Therapeutics, for a candid conversation about translational science, biotech leadership, and the realities of drug development. Drawing from his experience across academia, Big Pharma, and startups, Gareth shares lessons from working in the biotech ecosystem, leading complex biologics programs, and developing therapies for hearing loss and tinnitus. In this episode, you'll learn: Why translational science and patient impact became the driving force behind Gareth's move from academia into biotech. How emerging technologies like AI are reshaping drug discovery and development timelines. What separates successful preclinical programs from the ones that fail, and why patient-centered thinking matters from day one. Tune in to learn how biotech leaders are navigating the highs and lows of drug development while working to bring meaningful therapies to patients with unmet medical needs. Links: Connect with Gareth Willis, PhD, and learn about Otologic Pharmaceutics and Exosla Therapeutics. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Life Science Courses from Gareth: Pharmaceutical Portfolio Strategies: Governance and Portfolio Management Advanced Due Diligence in Pharmaceuticals Pharmacology Essentials Training: Understanding Pharmacology in Drug Development Mastering Development and Regulatory Strategies in Cell Therapy Learn more about Elaine's wine pub, The Study. Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

The ongoing outbreak of hantavirus infections that originated with passengers on the Dutch cruise ship MV Hondius in April has generated concerns across the globe. This very rare occurrence has led to a number of deaths, required quarantining of passengers and prompted emergency responses from public health authorities in multiple countries.  On this episode of Raise the Line from Elsevier, we're tapping the expertise of a leading authority on the subject, Dr. Jamie Childs of Yale University, to provide you with a scientific understanding of hantaviruses and what level of threat is posed by this situation. In short, Dr. Childs believes this is not the start of a pandemic. “The Andes variant involved here is one of the most dangerous hantaviruses, but it is totally controllable with contact tracing.” This timely conversation with host Lindsey Smith is informed by Dr. Childs' decades of hantavirus research as well as learnings from his role leading the CDC's environmental investigation during the landmark 1993 hantavirus outbreak in the Four Corners region of the American Southwest. And be sure to stay tuned to hear his concerns about the factors complicating containment of the current Ebola outbreak in East Africa. Note: this conversation was recorded on May 19th, 2026. Mentioned in this episode: Yale School of Public Health Yale Institute for Global Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Site feasibility remains a critical yet complex component of clinical trial startup. In this episode, listen as Andrea Bastek (VP, Market Strategy at Florence Healthcare), Christine Senn (SVP, Site-Sponsor Innovation at Advarra), and Ashley Davidson (SVP, Head of Product at Advarra) unpack the persistent challenges in feasibility -- from manual, time-intensive processes and data trust gaps to misaligned timelines and limited transparency between stakeholders.The conversation explores how collaboration, smarter process design, and emerging technologies like AI and real-time data integration can reduce burden on sites and improve study startup timelines. Guests also share practical recommendations, including simplifying CDA processes, improving communication between sponsors and sites, and leveraging data more effectively to move forward toward a more efficient and connected feasibility model.Resources:- Advarra CDA Template - Advarra Site ID Feasibility Solution- Paper from Florence Healthcare's Site Enablement League

We mark National Mental Health Awareness Month on this episode by tapping the expertise of Dr. Steve Strakowski, an internationally recognized expert in bipolar disorder, who has spent decades studying the neurobiology and treatment of mood conditions while pushing just as hard on the structural barriers that keep effective treatments out of reach for more than half the people who need them. In this conversation with Raise the Line from Elsevier host Michael Carrese, Dr. Strakowski explains why access, not science, is now the biggest obstacle to improving mental health outcomes. He also addresses the heavy toll society pays for underfunding mental health prevention and treatment programs. “The money is spent eventually, but in the most expensive places like emergency rooms and prisons, and there is the human cost of suffering and suicides." This important discussion also covers: The persistent problem of Black patients presenting with mania being misdiagnosed with schizophrenia;  Why he describes bipolar disorder as a reward-processing illness;  The emerging therapies he finds encouraging. Mentioned in this episode:Indiana University School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

"When the workforce does not align with the population, your system is misaligned by design." That candid observation comes from Tina Loarte-Rodríguez, DP, RN who has spent much of her two decade career in patient safety, risk management, and systems leadership as the only Latina in the room, which she sees as a signal of a systemic failure that demands structural solutions. As we mark National Nurses Month, Dr. Loarte-Rodríguez joins Raise the Line from Elsevier  host Lindsey Smith to explain why a culturally congruent workforce has important implications for access, trust and quality of care. This wide-ranging discussion also covers: What Dr. Loarte-Rodriguez means by "narrative infrastructure" and how a book series born during COVID is now shaping workforce conversations nationwide;   The case for making mentorship a core institutional system;   Why nursing burnout is not about a lack of resiliency.  Mentioned in this episode: Latinas in NursingThe Connecticut Center for Nursing Workforce If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

The doctor is in....the box.  That's one way to describe how patients are now encountering their physicians in what's being described as the future of telehealth. Imagine that instead of a cancer patient in a rural area driving hours for an appointment to see their specialist at an academic health center, they can go to their local clinic and see a life-size, real-time, 3-D projection of them in a seven foot tall light box.  The doctor can see the patient through two-way video, and is assisted by a clinician in the exam room. The technology behind this remarkable scene is provided by a Los Angeles based start-up called Proto Hologram, whose founder and chairman, David Nussbaum, joins us on this episode of Raise the Line from Elsevier. "Our holograms start where Zoom ends and where physically being there begins," says Nussbaum, a TIME Healthcare100 honoree who has spent the last decade developing commercial and educational applications for holograms.  In addition to clinical settings, Proto units are being used at medical schools and senior living facilities and are playing a role in public health campaigns about breast cancer and vaccines. Join host Lindsey Smith for a fascinating conversation that covers: The role of holograms in extending access to specialty care; How the technology could be used to combat loneliness among seniors; Nussbaum's philosophy of "commercializing the impossible". Mentioned in this episode: Proto Hologram If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast